News News Details

头条 | 深化合作、全球布局!倚锋参访国际顶级生物医药投资机构

Date: 2018-08-13
Views: 26


近期,倚锋资本董事总经理雒法涌、总裁助理朱湃率队赴美国纽约、波士顿、旧金山等地进行为期多天的参访调研。


倚锋团队此行旨在深化与国际知名投行之间的合作,分析探讨中美两国生物医药行业的发展现状和潜在的投资机会,并针对多个美国本土项目进行细致的调研和评估,筛选最具投资价值的项目,进一步完善倚锋资本在全球生物医药领域的投资布局。

 

纽约时间1015日,倚锋团队首先拜访了“老朋友”——Maxim Group


作为一家提供全方位金融服务的国际知名投行,Maxim Group建立了一个强大的多渠道平台,覆盖2000多家美国机构投资者,全球金融机构和高净值私人客户。


自2013年1月1日以来,Maxim Group一共参与了397笔交易,金额高达339亿美元,成为近几年最活跃的国际投行之一。


头条 | 深化合作、全球布局!倚锋参访国际顶级生物医药投资机构


此次参访中,双方回顾了Aridis、Centrexion等前期合作项目所取得的丰硕成果,一致认为深化合作可以发挥双方各自在中国和国际金融市场的独特优势,实现互利共赢。

 

倚锋团队还与Maxim Group重点探讨了多个新推项目的合作前景,拟定了后续合作的相关方案,同时针对倚锋资本部分在美投资项目的退出事宜深入交换了意见。

 

结束Maxim Group的参访之后,倚锋团队马不停蹄,来到了华尔街著名投行——Jefferies参访。


头条 | 深化合作、全球布局!倚锋参访国际顶级生物医药投资机构


Jefferies是美国生物医药领域的顶级投行之一,在2006、2007连续两年被评为“最佳中型市场投资银行”,并在2008年Vault Guide 的《世界最著名的50家银行》中排名第22位。在华尔街本土券商中排名第5位 

 

倚锋团队本次到访受到了Jefferies生物医药组的热情接待,双方就中美两国生物医药行业的发展现状和潜在的投资机会进行了非常友好的交流,并在项目推介、投后管理、IPO资源对接等多个领域达成广泛的合作共识。


头条 | 深化合作、全球布局!倚锋参访国际顶级生物医药投资机构


通过本次美国参访之旅,倚锋资本与国际顶级生物医药投资机构之间建立起了高效的业务对接渠道和互利共赢的合作模式。这将进一步丰富倚锋资本为国内外投资者所提供的金融服务, 同时也为国内优秀的生物医药企业提供更多参与国际资本市场的机会。


Related News / Recommended news More
2022 - 08 - 10
On August 9, the National Health Commission issued a notice, according to the approval opinions of the State Food and Drug Administration on the application for registration of additional indications for the treatment of novel coronavirus pneumonia with azvudine tablets. In order to further improve the antiviral treatment scheme for novel coronavirus pneumonia, the drug was included in the diagnos...
2022 - 08 - 05
Just recently, the Hong Kong Stock Exchange welcomed the successful submission of the first share of the new crown oral drug. On August 4, the Hong Kong Stock Exchange disclosed that Henan Zhenzhen Biotechnology Co., Ltd. (hereinafter referred to as 'Genuine Biotech') submitted a listing application to the Hong Kong Stock Exchange. Efung Capital is the only investment institution...
2022 - 08 - 01
Recently, Apexigen, a portfolio company of Efung Capital, and Brookline Capital Acquisition Corp.-a Special Purpose Acquisition Company (SPAC)-entered an official merger process, resulting that Brookline Capital Acquisition Corp. was renamed to Apexigen, Inc. Guided and led by Dr. Xiaodong Yang, president as well as Chief Executive Officer (CEO) of Apexigen company, the firm joined the listing of ...
2022 - 07 - 25
On July 25, 2022, the State Drug Administration proclaimed that, in accordance with the relevant provisions of the Drug Administration Law and specific drug approval procedures, the State Drug Administration conducted emergency review and approved Henan Zhenzhen Biotechnology Co., Ltd. with certain conditions. The registration application for Azvudine tablets to treat the novel coronavirus pneumon...
Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务